These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36994873)

  • 21. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease-related adverse events following non-live vaccines: investigation of a newly described reporting bias through the analysis of the WHO Global ICSR Database, VigiBase.
    Roberto G; Zanoni G
    Vaccine; 2014 May; 32(26):3328-35. PubMed ID: 24291198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suspected cutaneous adverse drug reactions reported with traditional medicines: analysis of data for United Nations Asia region from WHO VigiBase.
    Barvaliya MJ; Chetan AC; Chandan N; Ray SK; Hegde HV; Unger BS; Patel TK; Roy S
    Front Pharmacol; 2023; 14():1088841. PubMed ID: 37324461
    [No Abstract]   [Full Text] [Related]  

  • 24. Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre.
    Star K; Sandberg L; Bergvall T; Choonara I; Caduff-Janosa P; Edwards IR
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):680-689. PubMed ID: 30767342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.
    Strandell J; Caster O; Bate A; Norén N; Edwards IR
    Drug Saf; 2011 Mar; 34(3):253-66. PubMed ID: 21332249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allergy-Like Immediate Reactions with Herbal Medicines: A Retrospective Study Using Data from VigiBase®.
    Pokladnikova J; Meyboom RH; Meincke R; Niedrig D; Russmann S
    Drug Saf; 2016 May; 39(5):455-64. PubMed ID: 26936182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database.
    Montastruc JL; Lafaurie M; de Canecaude C; Durrieu G; Sommet A; Montastruc F; Bagheri H
    Br J Clin Pharmacol; 2021 Nov; 87(11):4334-4340. PubMed ID: 33837554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.
    Comfort S; Perera S; Hudson Z; Dorrell D; Meireis S; Nagarajan M; Ramakrishnan C; Fine J
    Drug Saf; 2018 Jun; 41(6):579-590. PubMed ID: 29446035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.
    Cliff-Eribo KO; Choonara I; Dodoo A; Darko DM; Sammons H
    Expert Opin Drug Saf; 2015; 14(12):1827-33. PubMed ID: 26436964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
    Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
    Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
    Lee S; Yang JW; Jung SY; Kim MS; Yon DK; Lee SW; Kang HC; Dragioti E; Tizaoui K; Jacob L; Koyanagi A; Salem JE; Kostev K; Lascu A; Shin JI; Kim JH; Smith L
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7390-7397. PubMed ID: 34919240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database.
    Strandell J; Wahlin S
    Eur J Clin Pharmacol; 2011 Jun; 67(6):633-41. PubMed ID: 21253716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase.
    Roselli A; Khouri C; Roustit M; Blaise S; Cracowski JL
    Dermatol Surg; 2019 Dec; 45(12):1517-1528. PubMed ID: 30829775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India.
    Kalaiselvan V; Sharma S; Singh GN
    Drug Saf; 2014 Sep; 37(9):703-10. PubMed ID: 25085041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database.
    Chen X; Wei L; Chi L; Guo X; Chen C; Guo Z; Liang J; Zheng Y; He J; Ye X
    Br J Clin Pharmacol; 2022 May; 88(5):2180-2189. PubMed ID: 34786743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
    Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
    Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
    Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
    Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.
    Wallerstedt SM; Brunlöf G; Sundström A
    Drug Saf; 2011 Aug; 34(8):669-82. PubMed ID: 21751827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.